Hungary

Hungarian leader Gedeon Richter spoke at length of its recent European roll-out of generic competition to Bayer’s Xarelto blockbuster, while also providing key updates for its biosimilar pipeline, as the firm reported financial first-half results.

Gedeon Richter is looking to chart its own path in women’s healthcare and expand its global footprint, after buying up a bundle of businesses and key products and pipeline assets from Belgium’s Mithra.

With two M&A deals expected to close in the second quarter, Gedeon Richter counts its wins and losses from a “solid” start to the year.

While investigating the potential of the Japanese market for its denosumab, Gedeon Richter is preparing for several regulatory filings, including its tocilizumab biosimilar.

Fledgling biosimilars player Gedeon Richter has spoken candidly and openly with investors on its recent biosimilar investments, its goal to start generate cash from its young Biotech business, and its need to manage costs in order to make that happen.

Gedeon Richter is putting its hand back in its wallet following its recent investment in Formycon, opting to take control of a pair of joint ventures established with German firm Helm.

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Ceres Pharma will grow its presence in Hungary, adding consumer health brands including 1x1 Vitamin and Innopharm supplements and Medistus medical devices, through its acquisition of Budapest's VitaPlus.

The proposed European Health Data Space aims to enable the seamless transition of health data sharing for certain purposes across the EU. A new report highlights how national variations in data storage and budgetary constraints may affect the initiative’s success.

The latest notified body listing brings total number of EU designated Medical Device Regulation testing and certification organizations to 35.

Gedeon Richter is keeping a keen eye on further business development opportunities, including M&A. The company is also continuing to tackle the impact of Russia’s invasion of Ukraine, observing that “there’s still not very much clarity on how the situation will evolve.”

Hungary’s Gedeon Richter is continuing to divert the greatest proportion of its R&D cash to biosimilars. Management updated on its pipeline and broader group prospects amid Russia’s military invasion of Ukraine.

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Gedeon Richter aims to continue the global roll-out of its teriparatide biosimilar, having enjoyed continued solid growth for the Forsteo rival during the first quarter.

Hungary’s Gedeon Richter achieved record results in 2020, driven by a near trebling of the firm’s group operating profit and rising sales. Management once again had much to say on the company’s biosimilar ambitions.

Hungary is going its own way when it comes to coronavirus vaccines, but its decision to allow the emergency use of the Oxford University/AstraZeneca vaccine may be only a symbolic expression of the government’s growing impatience with the EU.

Hungarian firm Gedeon Richter is to expand further its sizeable women’s health portfolio after agreeing to acquire Janssen’s Evra (ethinyl estradiol/norelgestromin) transdermal patch outside of the US for more than a quarter of a billion dollars.

Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.

Hungary’s Gedeon Richter is continuing efforts to bring multiple biosimilars to market, while reaping the benefits of the biosimilar to Eli Lilly’s Forsteo (teriparatide) in the EU and Japan. Management discussed Richter’s achievements on the company’s first-half earnings call, while also commenting on how markets have reacted to the COVID-19 pandemic.

Gedeon Richter has high ambitions for biosimilars, recently penning a deal to bring in a tocilizumab biosimilar that is currently under development. During its first-quarter earnings call, the Hungarian company’s CEO gave his current thinking on how payers may treat biosimilars amidst the COVID-19 pandemic.